Nilvadipine shows no benefit for the treatment of Alzheimer's disease in mild and moderate stages of the disease, but further studies targeting the early phase of the disease may be warranted.
Source: Care Giving Science Daily
Challenge continues in developing effective drug treatment for Alzheimer's disease
September 24th, 2018 | Posted by in UncategorizedYou can follow any responses to this entry through the RSS 2.0 You can leave a response, or trackback.
Leave a Reply